Between the failure at G20 and Moderna’s exclusive patent claim—ignoring NIH’s role and public funding—it’s been a bad week for vaccine equity.
Covid Vaccine Equity, G20 And Moderna
Between the failure at G20 and Moderna’s exclusive patent claim—ignoring NIH’s role and public funding—it’s been a bad week for vaccine equity.